IQVIA Institute for Human Data Science. Medicine use and spending in the U.S. https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/medicine-use-and-spending-in-the-us---a-review-of-2018-outlook-to-2023.pdf. 2019. Accessed 16 Feb 2021.

Chen BK, Yang YT, Bennett CL. Why biologics and biosimilars remain so expensive: despite two wins for biosimilars, the Supreme Court’s recent rulings do not solve fundamental barriers to competition. Drugs. 2018;78(17):1777–81.

Article  Google Scholar 

Makurvet FD. Biologics vs. small molecules: drug costs and patient access. Med Drug Discov. 2021;9:100075.

CAS  Article  Google Scholar 

Blum MA, Koo D, Doshi JA. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review. Clin Ther. 2011;33(7):901–13.

Article  Google Scholar 

Modena V, Bianchi G, Roccatello D. Cost-effectiveness of biologic treatment for rheumatoid arthritis in clinical practice: an achievable target? Autoimmun Rev. 2013;12(8):835–8.

CAS  Article  Google Scholar 

IQVIA Institute for Human Data Science. Biosimilars in the United States, 2020-2024. https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/iqvia-institute-biosimilars-in-the-united-states.pdf. 2020. Accessed 17 Feb 2021.

U.S. Food and Drug Administration. Biosimilar and interchangeable products. https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-products. Updated October 23, 2017. Accessed 2 Mar 2022.

U.S. Food and Drug Administration (FDA). Biosimilar product information. https://www.fda.gov/drugs/biosimilars/biosimilar-product-information. Updated February 25, 2022. Accessed 2 Mar 2022.

Kang H-N, Thorpe R, Knezevic I. The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019. Biologicals. 2020;65:1–9.

CAS  Article  Google Scholar 

Kang H-N, Thorpe R, Knezevic I, et al. Biosimilars—status in July 2020 in 16 countries. GaBI J. 2020;10(1):4–33.

Article  Google Scholar 

Druedahl LC, Kälvemark Sporrong S, Minssen T, Hoogland H, De Bruin ML, et al. Interchangeability of biosimilars: a study of expert views and visions regarding the science and substitution. PLoS ONE. 2022;17(1): e0262537.

CAS  Article  Google Scholar 

Amgen. 2021 biosimilars trends report. https://www.amgenbiosimilars.com/commitment/trends-report? Accessed 26 May 2022.

Karaca-Mandic P, Chang J, Go R, Schondelmeyer S, Weisdorf D, Jeffery MM. Biosimilar filgrastim uptake and costs among commercially insured, Medicare advantage. Health Aff. 2019;38(11):1887–92.

Article  Google Scholar 

Socal MP, Anderson KE, Sen A, Bai G, Anderson GF. Biosimilar uptake in Medicare Part B varied across hospital outpatient departments and physician practices: the case of filgrastim. Value Health. 2020;23(4):481–6.

Article  Google Scholar 

U.S. Food and Drug Administration. Office of generic drugs: 2021 annual report. https://www.fda.gov/media/156066/download. 2022. Accessed 26 May 2022.

Cornes P. The economic pressures for biosimilar drug use in cancer medicine. Target Oncol. 2012;7:57–67.

Article  Google Scholar 

Yu B. Greater potential cost savings with biosimilar use. Am J Manag Care. 2016;22(5):378.

PubMed  Google Scholar 

IQVIA Institute for Human Data Science. The impact of biosimilar competition in Europe. https://www.iqvia.com/-/media/iqvia/pdfs/library/white-papers/the-impact-of-biosimilar-competition-in-europe-2021.pdf. 2021. Accessed 30 June 2022.

Atteberry P, Bach PB, Ohn JA, Trusheim MR. Biologics are natural monopolies (Part 1): why biosimilars do not create effective competition. Health Aff Blog. 2019. https://doi.org/10.1377/hblog20190405.396631/full. Accessed 16 Feb 2021.

Cohen H, Beydoun D, Chien D, Lessor T, McCabe D, Muenzberg M, Popovian R, Uy J. Awareness, knowledge, and perceptions of biosimilars among specialty physicians. Adv Ther. 2016;33:2160–72.

Article  Google Scholar 

Sarnola K, Merikoski M, Jyrkka J, Hameen-Anttila K. Physicians’ perceptions of the uptake of biosimilars: a systematic review. BMJ Open. 2020;10(5): e034183.

Article  Google Scholar 

Barbier L, Vandenplas Y, Simoens S, Declerck P, Vulto AG, Huys I. Knowledge and perception of biosimilars in ambulatory care: a survey among Belgian community pharmacists and physicians. J Pharm Policy Pract. 2021;14:53.

Article  Google Scholar 

Barbier L, Simoens S, Vulto AG, Huys I. European stakeholder learnings regarding biosimilars: Part 1—improving biosimilar understanding and adoption. BioDrugs. 2020;34:783–96.

Article  Google Scholar 

Herndon K, Braithwaite J, Berry B, Bourget K. Biosimilar perceptions among healthcare professionals and commercial medical benefit policy analysis in the United States. BioDrugs. 2021;35:103–12.

Article  Google Scholar 

Lewek P, et al. Factors affecting the opinions of family physicians regarding generic drugs: a questionnaire-based study. Bosn J Basic Med Sci. 2015;15(1):45–50.

PubMed Central  Google Scholar 

Liou WS, et al. Brand name or generic? What are the health professionals prescribed for treating diabetes? A longitudinal analysis of the National Health Insurance reimbursement database. Pharmacoepidemiol Drug Saf. 2013;22(7):752–9.

Article  Google Scholar 

Shrank WH, et al. Physician perceptions about generic drugs. Ann Pharmacother. 2011;45(1):31–8.

Article  Google Scholar 

Polinski JM, et al. Does knowledge of medication prices predict physicians’ support for cost effective prescribing policies. Can J Clin Pharmacol. 2008;15(2):e286–94.

PubMed  PubMed Central  Google Scholar 

Kaida-Yip F, Deshpande K, Saran T, Vyas D. Biosimilars: review of current applications, obstacles, and their future in medicine. World J Clin Cases. 2018;6(8):161–6.

Article  Google Scholar 

Shakeel S, Hassali MA, Rehman H, Rehman AU, Muneswarao J. Knowledge, attitude, and practice towards biosimilars and interchangeable products: a prescriptive insight by the pharmacists. Int J Gen Med. 2020;13:1075–82.

Article  Google Scholar 

Greene L, Singh RM, Carden MJ, Pardo CO, Lichtenstein GR. Strategies for overcoming barriers to adopting biosimilars and achieving goals of the Biologics Price Competition and Innovation Act: a survey of managed care and specialty pharmacy professionals. J Manag Care Spec Pharm. 2019;25(8):904–12.

PubMed  Google Scholar 

Beck M, Michel B, Rybarczyk-Vigouret M-C, Leveque D, Sordet C, Sibilia J, Velten M. Knowledge, behaviors, and practices of community and hospital pharmacists toward biosimilar medicines: results of a French web-based survey. MAbs. 2017;9(2):383–90.

Article  Google Scholar 

Arnet I, Verbeek M, Almarsdóttir AB, Barbier L, Clifford R, Eickhoff C, et al. Community pharmacists’ preparedness for substituting biologics and dispensing biosimilars: lessons learned from a multinational survey. Explor Res Clin Soc Pharm. 2021;4: 100084.

PubMed  PubMed Central  Google Scholar 

Leonard E, Wascovich M, Oskouei S, Gurz P, Carpenter D. Factors affecting health care provider knowledge and acceptance of biosimilar medicines: a systematic review. J Manag Care Spec Pharm. 2019;25(1):102–12.

PubMed  Google Scholar 

Aladul MI, Fitzpatrick RW, Chapman SR. Differences in U.K. healthcare professionals’ knowledge, attitude, and practice toward infliximab and insulin glargine biosimilars. Int J Pharm Pract. 2019;27(2):214–7.

Article  Google Scholar 

Barbier L, Simoens S, Vulto AG, Huys I. European stakeholder learnings regarding biosimilars: Part 2—improving biosimilar use in clinical practice. BioDrugs. 2020;34:797–808.

Article  Google Scholar 

Yang J, Blinzler K, Lankin J, Vijayakumar S, Maculaitis MC, Shelbaya A. Evolving perceptions, utilization, and real-world implementation experiences of oncology monoclonal antibody biosimilars in the USA: perspectives from both payers and physicians. BioDrugs. 2022;36:71–83.

CAS  Article  Google Scholar 

Morgan D. The Focus Group Guidebook. Thousand Oaks: Sage Publications; 1998.

Book  Google Scholar 

Giacomini MK, Cook DJ. Users’ guides to the medical literature: XXIII. Qualitative research in health care B. What are the results and how do they help me care for my patients? Evid-Based Med Work Group JAMA. 2000;284(4):478–82.

CAS  Google Scholar 

Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the analysis of qualitative data in multi-disciplinary health research. BMC Med Res Methodol. 2013;13:117. https://doi.org/10.1186/1471-2288-13-117.

Article  PubMed  PubMed Central  Google Scholar 

Tie YC, Birks M, Francis K. Grounded theory research: a design framework for novice researchers. Sage Open Med. 2019;7:2050312118822927.

Google Scholar 

Miles M, Huberman A. Qualitative Data Analysis. Thousand Oaks: Sage Publications; 1994.

Google Scholar 

U.S. Food and Drug Administration. What is the approval process for generic drugs? https://www.fda.gov/drugs/generic-drugs/what-approval-process-generic-drugs. Accessed 31 May 2022.

Cardinal Health. Biosimilars Report: The U.S. Journey and Path Ahead. Dublin: Cardinal Health; 2022.